Biomemory launches DNA Shield, its first commercial product on the Molecular IT platform
Baseado só no resumo do feed. O site da fonte não liberou o texto completo para o Tifon, então esta análise saiu apenas do resumo publicado no feed e pode estar incompleta. Ela é atualizada quando outra fonte cobrir o assunto. Ler na fonte original ↗
Biomemory has launched DNA Shield, the first commercial product built on its Molecular IT platform. The launch follows Biomemory's acquisition of catalog's assets and the appointment of Laurent Guengant as CEO earlier this year. The article is product and business news. It describes no vulnerability, incident, threat actor or indicator, and it gives no technical detail on how DNA Shield works. It has no direct operational impact for defenders.
Linha do tempo
-
darkreading.com ↗ · pub. 16/10/2026 16:22 · coletado 19/10 17:54 primeiro registro só resumo do feed
Biomemory launches DNA Shield, its first commercial product on the Molecular IT platform
ler a análise desta fonte ocultar
Biomemory has launched DNA Shield, the first commercial product built on its Molecular IT platform. The launch follows Biomemory's acquisition of catalog's assets and the appointment of Laurent Guengant as CEO earlier this year. The article is product and business news. It describes no vulnerability, incident, threat actor or indicator, and it gives no technical detail on how DNA Shield works. It has no direct operational impact for defenders.